100th ReWalk Exoskeleton Supplied in Germany

ReWalk Robotics
Share on linkedin
Share on facebook
Share on twitter
Share on print
Share on email
Press Contacts

ReWalk Media Relations:

John Tomlin
E: [email protected]

ReWalk Investor Contact:
Almog Adar
Director of Finance
ReWalk Robotics Ltd.
T: +972-4-9590130
E: [email protected]

21-year-old Lukas Gloßner from Nürnberg is the 100th paraplegic in Germany to be provided with a ReWalk Personal Exoskeleton

BERLIN, June 23, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics, Ltd (Nasdaq: RWLK) (“ReWalk” or “the Company”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announces the 100th placement of an exoskeleton in Germany. The first official reimbursement for a ReWalk exoskeleton supply was by the German statutory accident insurance in June 2015.

ReWalk’s mission is to fundamentally change the quality of life for people with lower extremity disabilities through the manufacture and development of market leading robotic technology. ReWalk Robotics has entered into framework agreements with several German health insurance companies to provide ReWalk exoskeletons. These contracts enable all eligible paraplegics to be supplied with an exoskeleton for personal use to stand, walk, and climb stairs during everyday activities at home and in their community (stairs function not yet available in the US). The delivery of this most recent system to ReWalker Lukas Gloßner marks the 100th insured person in Germany who has now been supplied with a ReWalk Exoskeleton.

Back in 2018, Lukas Gloßner, 21, used a borrowed ReWalk Exoskeleton for an important occasion: “After the first training phase, I was able to pick up my high school diploma on foot at the award ceremony back then,” the young man recalls. He already knows exactly how he wants to receive his bachelor’s degree certificate after graduation: upright and walking in his own ReWalk device.

Lukas, who has been a paraplegic since a moped accident at the age of 16, is delighted with the receipt of his ReWalk medical device. He plays wheelchair basketball in the second German national league, is part of the U22 national wheelchair basketball team, and was runner-up in the 2021 European Championships. “I try to keep myself as fit as possible,” Gloßner tells us. “But I also know that over the years in a wheelchair, your health can decline. So I hope to maintain my health as long as possible by standing and walking. I am looking forward to a daily routine with an upright gait in the ReWalk Exoskeleton. The fact that I am the 100th paraplegic in Germany to be supplied with a ReWalk system is a special honor. “

“For us, the 100th placement of a ReWalk exoskeleton in Germany is an important milestone on the way to improving the quality of life of paraplegic people,” says Larry Jasinski, CEO of ReWalk Robotics. “We wish Lukas all the best in his next steps.”

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit rewalk.com.

ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other Jurisdictions.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: uncertainties associated with future clinical trials and the clinical development process, the product development process and U.S. Food and Drug Administration (“FDA”) regulatory submission review and approval process; the adverse effect that the COVID-19 pandemic has had and may continue to have on the Company’s business and results of operations; ReWalk’s ability to have sufficient funds to meet certain future capital requirements, which could impair the Company’s efforts to develop and commercialize existing and new products; ReWalk’s ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors, including the Centers for Medicare & Medicaid Services (CMS), for its products; ReWalk’s limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk’s ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to obtain clearance from the FDA for use of the ReWalk Personal device on stairs; ReWalk’s compliance with medical device reporting regulations to report adverse events involving its products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of ReWalk’s IT systems significantly disrupting its business operations; ReWalk’s ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading “Risk Factors” in ReWalk’s annual report on Form 10-K and 10-K/A for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Share on linkedin
Share on facebook
Share on twitter
Share on print
Share on email
MEDICA 2022 banner

Where healthcare is going.
MEDICA 2022 – Top in all medical areas

We are at Hall 17 / A07

tradewinds booth location at MEDICA 2022

TradeWinds Consulting

Are you in?

Subscribe to receive exclusive content and notifications to your inbox